1. Home
  2. LGI vs IMUX Comparison

LGI vs IMUX Comparison

Compare LGI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lazard Global Total Return and Income Fund

LGI

Lazard Global Total Return and Income Fund

HOLD

Current Price

$18.70

Market Cap

242.3M

Sector

N/A

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$14.76

Market Cap

209.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGI
IMUX
Founded
2004
2016
Country
United States
United States
Employees
N/A
66
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
242.3M
209.2M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
LGI
IMUX
Price
$18.70
$14.76
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$36.00
AVG Volume (30 Days)
32.5K
182.6K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
7.10%
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.32
$0.51
52 Week High
$19.88
$15.84

Technical Indicators

Market Signals
Indicator
LGI
IMUX
Relative Strength Index (RSI) 63.68 58.08
Support Level $18.69 $0.74
Resistance Level $19.30 $15.81
Average True Range (ATR) 0.22 0.90
MACD 0.05 -0.17
Stochastic Oscillator 76.67 40.69

Price Performance

Historical Comparison
LGI
IMUX

About LGI Lazard Global Total Return and Income Fund

Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: